Study
Mind-Body Reprocessing Therapy and Nicotinamide Riboside in Long COVID: a 2x2 Factorial Randomised Controlled Trial (Phase 2)
Norwegian trial randomised 310 adults with long COVID to nicotinamide riboside 2000 mg/day or placebo for 84 days, crossed with a psychological therapy. Data collection finished 23 June 2025. No results posted.
NCT05703074 randomised 310 adults aged 18 to 70 with long COVID in a 2x2 factorial design. One factor was nicotinamide riboside against matching placebo: four capsules twice daily, 1000 mg per dose, 2000 mg per day, for 84 days. The other factor was Mind-Body Reprocessing Therapy, four to six face-to-face sessions over three to four weeks plus online resources, against care as usual with a self-help leaflet. For the supplement comparison the masking is quadruple: participant, care provider, investigator and outcomes assessor. For the therapy comparison only the outcomes assessor is blinded.
The primary outcome is the general health subscore of the SF-36 at three months. Secondary outcomes are high-sensitivity CRP, Trail Making Test part B, cost-effectiveness, and patient-reported fatigue on the Chalder Fatigue Questionnaire, dyspnoea on the MRC scale, and global impression of change.
Vegard Wyller is principal investigator and Torbjørn Omland is study chair, both at Akershus University Hospital and the University of Oslo. Recruitment started 30 January 2023. Primary completion was 23 September 2024 and the trial closed 23 June 2025. The registry entry was updated 22 August 2026 with status completed and no results posted.
This is one of the two largest nicotinamide riboside trials to have finished data collection. At 310 participants it is more than five times the size of the 58-person Boston long-COVID trial published in EClinicalMedicine in November 2025, which found no cognitive benefit at 2000 mg per day. A completed trial with no posted results carries no efficacy evidence, so it does not move our nicotinamide riboside rating. We list it because the readout will be the largest test of this dose in a symptomatic population.
No results have been posted. The registry lists the trial as completed with data collection ending 23 June 2025.
The factorial design means the supplement effect is estimated across two therapy conditions, which reduces power for any interaction. The 2000 mg per day dose is two to seven times what nicotinamide riboside products on this site provide per serving, so a null result would not automatically transfer to normal consumer dosing. Long COVID is a symptomatic patient population, not healthy ageing.
Noted and monitored. No change to the nicotinamide riboside rating.
A completed registration with no posted results is not evidence. Our rules require a published human randomised trial or a meta-analysis before a rating moves. We list it because at 310 participants it is the largest finished nicotinamide riboside trial we know of and the result will matter either way.
- Results posting on ClinicalTrials.gov: SF-36 general health subscore at three months
- A results publication in a peer-reviewed journal by Wyller or Omland
- High-sensitivity CRP, which would show whether the dose changed inflammation
- Any reported adverse events at 2000 mg per day over 84 days
- Whether the factorial design reports the supplement effect separately from the therapy effect
Expected readout: Results overdue. Data collection ended 23 June 2025 and nothing was posted as of 26 August 2026. · Decision recorded 2026-08-26
Cited by
1 encyclopedia entries reference this study.